Base Editing Rewrites PCSK9 in Human Embryos Without DNA Breaks, Study Finds

For years, the dream of correcting disease-causing DNA in human embryos has been shadowed by a hard biological reality: the most powerful genome-editing tools work by cutting DNA, and cuts in the fragile genome of a newly fertilized egg can be catastrophic. A new study published in Nature by a large international team led by Dieter Egli of Columbia University now reports a strikingly different outcome when the cuts are removed from the equation. Instead of using Cas9 nucleases that slice both strands of the DNA double helix, the researchers deployed a base editor, a molecular machine that chemically converts one DNA letter into another without ever severing the backbone. When delivered as a protein at the moment of fertilization, the editor rewrote the PCSK9 gene in every copy of the gene in the treated embryos, and those embryos went on to develop to the blastocyst stage, the milestone at which embryos are typically evaluated in laboratory research.

The significance of that result becomes clear when it is set against the track record of double-strand break editing in human embryos. Previous work had shown that Cas9-induced breaks are genotoxic in this setting, producing frequent aneuploidy, a condition in which cells end up with the wrong number of chromosomes, as well as large deletions that scramble the very region the edit was meant to correct. The reason lies in how embryos handle broken DNA. Early human embryos rely on relatively inefficient and error-prone repair pathways, so a deliberate double-strand break can cascade into chromosome loss, mosaicism in which different cells carry different genomes, and developmental arrest. By contrast, the lesions created by base editors, single-strand nicks and mismatched base pairs, appear to be handled far more gracefully by the embryo’s repair machinery, and the new study provides the most direct evidence yet that this is the case.

The base editor at the heart of the experiment, known as ABE8e-V106W, belongs to the adenine base editor family. These enzymes fuse a Cas9 variant that nicks only one DNA strand to an engineered deaminase enzyme that chemically converts adenine into inosine, a nucleotide that the cell’s replication and repair machinery reads as guanine. The result is a targeted A-to-G transition, or, on the opposite strand, a T-to-C change. The V106W mutation in the deaminase domain is a precision refinement designed to constrain the enzyme’s activity window and reduce collateral edits at nearby positions. In the study, the team targeted the editor at the PCSK9 locus, a gene whose loss-of-function variants are known to lower LDL cholesterol dramatically and protect against cardiovascular disease, and at the HBG locus, a fetal hemoglobin gene relevant to blood disorders.

Delivery was a critical design choice. The researchers introduced the editor as a purified protein together with its guide RNA at fertilization, rather than as messenger RNA or DNA that would force the embryo to manufacture the enzyme itself. Protein delivery has a built-in advantage: the enzyme is present immediately but is also degraded quickly, limiting the window during which off-target editing can occur. With this approach, editing was achieved at all PCSK9 alleles, meaning both the maternal and paternal copies of the gene were converted in the edited embryos. The team then derived homozygous edited stem cell lines from the resulting blastocysts, confirming that the edit had been installed uniformly and could be propagated through cell division. Notably, sequencing detected no insertions or deletions at the target site, the class of collateral damage that most commonly accompanies nuclease-based editing.

Yet the study is emphatically not a green light for editing human reproduction. Although the overall picture was far cleaner than with Cas9 breaks, the researchers documented rare on-target chromosome breakage and other chromosomal abnormalities among the treated embryos. These events were infrequent, but in the context of reproductive medicine even a low rate of chromosomal damage is a serious concern, because an embryo carrying such an abnormality could, in principle, develop into a pregnancy with severe consequences. The findings underscore a recurring theme in genome editing: eliminating one failure mode does not eliminate risk, it merely shifts the risk profile, and every new editing modality must be evaluated on its own terms in the most sensitive biological context available.

Two further problems emerged that complicate the picture. First, editing at bystander sites, positions within the enzyme’s activity window near the intended target, and at off-target sites elsewhere in the genome was mosaic, meaning that only a subset of cells in a given embryo carried the unintended edits. Mosaicism is particularly troublesome because it makes it difficult to verify the final genetic makeup of an embryo from a single biopsy, and it means that some cell lineages could carry edits that others do not. Second, and more dramatically, when the team delivered the editor as mRNA instead of protein, the embryos frequently arrested in development. The culprit was guide-independent deaminase activity: the deaminase portion of the editor, once produced in abundance inside the embryo, chemically modified adenines in RNA and DNA without needing the guide RNA to direct it, and this untargeted activity proved toxic to early development.

That observation carries a broader lesson for the base-editing field. Much of the enthusiasm for adenine base editors has come from work in cell lines and animal models, where high expression of the editor is generally a virtue, driving editing efficiency upward. In a human zygote, however, the calculus inverts. A transient burst of enzyme activity, tightly constrained in time and directed by the guide RNA, is tolerable; a sustained flood of deaminase that wanders off its intended target is not. The contrast between the protein-delivered and mRNA-delivered experiments in this study provides an unusually clean demonstration that the delivery format, not just the editor itself, determines whether editing is compatible with normal embryonic development.

The choice of PCSK9 as the target gene is also worth unpacking. Loss-of-function mutations in PCSK9 are among the most celebrated protective variants in human genetics: people born with them have low LDL cholesterol and sharply reduced rates of heart disease, and this biology has already inspired a generation of cholesterol-lowering drugs, including PCSK9-targeting antibodies and, more recently, CRISPR-based therapies in adults. Editing PCSK9 in an embryo would, in theory, confer lifelong protection from birth. The HBG target, meanwhile, speaks to the reactivation of fetal hemoglobin as a strategy for sickle cell disease and beta-thalassemia. By demonstrating efficient editing at both loci, the study connects embryo-level genome engineering to two of the most clinically mature gene-editing applications in medicine today.

The authors are explicit in their conclusion that undesirable consequences for the genome and development currently preclude clinical use of this technology in reproduction. That caution matters because the regulatory and ethical landscape surrounding human embryo editing remains fraught, particularly after the 2018 case in which embryos were edited with Cas9 and led to the birth of children in China, an experiment widely condemned for its safety failures and ethical lapses. The new work does not change the ethical calculus, but it does change the technical one. It shows that the genotoxicity that made nuclease editing in embryos so dangerous is not an inherent property of all genome editing, but a consequence of how double-strand breaks are repaired in early development. In that sense, the study reframes the debate: the question is no longer only whether embryo editing should be done, but which molecular strategies, if any, could ever make it safe enough to consider.

What comes next will likely focus on engineering away the remaining hazards. Reducing guide-independent deaminase activity, narrowing the editing window to eliminate bystander edits, improving the specificity of guide RNAs to suppress off-target activity, and refining delivery to minimize chromosomal damage are all active areas of enzyme engineering, and the detailed datasets accompanying this study, including genome-wide off-target maps and single-embryo sequencing analyses, provide a benchmark against which future editor versions can be measured. The derivation of homozygous edited stem cell lines also offers a renewable experimental platform for studying the long-term consequences of precise edits in a human genomic context. For now, the study stands as a technical landmark and a sober warning at once: base editing can rewrite the human embryonic genome with remarkable efficiency and without the catastrophic breaks of earlier methods, but the genome of a human embryo remains an unforgiving place to work, and no current technology is ready to touch it in the clinic.

Subject of Research: Adenine base editing of the PCSK9 gene in human embryos and its effects on genome integrity and development

Article Title: Highly efficient base editing at PCSK9 and normal human embryo development

Article References: Jerabek, S., Jung, C., Kappy, M., Zhao, Q., Sung, J., Wang, N., Kim, E., Kim, J., Kulmann, M. I. R., King, M. B., McAndrew, M. J., Li, M., Bhatele, S., Isado, M., Jang, H.-S., Dolezal, M., Prosser, R., Xu, S., Hwang, G.-H., … Egli, D. (2026). Highly efficient base editing at PCSK9 and normal human embryo development. Nature. https://doi.org/10.1038/s41586-026-11118-x

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11118-x

Keywords: base editing, human embryos, PCSK9, ABE8e, genome editing, aneuploidy, mosaicism, blastocyst, embryonic stem cells, chromosomal abnormalities, gene therapy, Columbia University